Skin reactions to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia

Pediatr Dermatol. 2024 Jan-Feb;41(1):169-176. doi: 10.1111/pde.15505. Epub 2023 Dec 27.

Abstract

Cutaneous adverse events are commonly reported in adult patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKIs); however, little is known about the cutaneous reactions in children receiving TKIs for CML. As pediatric patients may require lifelong TKI therapy, it is essential to understand the wide range of potential cutaneous toxicities. We examined all case studies, cohort studies, and clinical trials in PubMed/MEDLINE and Embase that reported cutaneous reactions to first-, second-, and third-generation TKIs in children 18 years or younger with CML. This review article focuses on the TKI drug types and doses, patient demographic characteristics, features of skin reactions, and clinical outcomes.

Keywords: chemotoxicity; chronic myeloid leukemia (CML); cutaneous adverse reactions; pediatrics; tyrosine kinase inhibitors (TKIs).

Publication types

  • Review

MeSH terms

  • Administration, Cutaneous
  • Adult
  • Child
  • Cohort Studies
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / chemically induced
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
  • Protein Kinase Inhibitors / adverse effects
  • Tyrosine Kinase Inhibitors*

Substances

  • Tyrosine Kinase Inhibitors
  • Protein Kinase Inhibitors